SPECIAL REPORT
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Pro-Bailout Greeks Regain Lead in Polls Before Vote
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
Roche To Genentech: Deal Or No Deal?
 |
The Swiss drug company is now offering 93 bucks a share for the 44 percent of DNA it doesn't already own. That's up from $86.50, which was down from the original bid of $89. Interestingly, Roche made the move on a Friday evening in Switzerland, in the middle of the trading day here in the States.
Roche, in the role of Howie Mandel who is a proxy for "the banker", is essentially trying to get Genentech shareholders to throw in the towel and take the $93 and go home. But there's still one briefcase left to be opened. It contains the results of the big study of Genentech's Avastin on earlier stage colon cancer. Analysts say if the drug works that it could add several billion dollars a year in revenue and send DNA [DNA
Loading...
()
] shares to around $100 and maybe even out of Roche's reach.
Clearly, Roche is trying to get this deal done before the results come out and it's counting on nervous shareholders, who might also need the cash right now in today's stock market, to take the bait. I think a key statement in the Roche release is Chairman Franz Humer's quote, "Based on conversations with Genentech shareholders, we believe there is a strong sentiment to bring this process to a conclusion."
But Genentech has already put out its own press release urging shareholders to leave it alone. The company says the three members of its board who make up the special committee assigned to deal with Roche will review the latest offer "promptly" and then explain its position "in detail" in a regulatory filing.
Game on.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
